Peripheral markers. Apolipoprotein E genotyping as a diagnostic adjunct for Alzheimer's disease

International Psychogeriatrics

Volumn 9, Issue SUPPL. 1, 1997, Pages 277-288

  Roses, Allen D ^a,b   Saunders, Ann M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Dept of Neurology and Neurobiology ^*

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ALLELE; ALZHEIMER DISEASE; CONFERENCE PAPER; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; ONSET AGE; PREDICTION; AGED; ARTICLE; GENETICS; MIDDLE AGED; PREDICTION AND FORECASTING;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; GENOTYPE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 0031441991     PISSN: 10416102     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1041610297005012     Document Type: Conference Paper

References (28)

1. Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., et al. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature and Genetics, 7, 180-184.
2. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261, 921-923.
3. Elston, R. C., & Johnson, W. D. (1994). Essentials ofbiostatistics (2nd ed.), Philadelphia: Davis.
4. Haines, J. L., Pritchard, M. L., Saunders, A. M., Schildkraut, J. M., Growdon, J. H., et al. (1996). No genetic effect of alpha(1)-antichymotrypsin in Alzheimer disease. Genomics, 3, 53-56.
5. Jobst, K. A., Smith, A. D., Szatmari, M., Esiri, M. M., Jaskowski, A., et al. (1994). Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet, 343, 829-830.
6. Kakulas, B. A., Wilton, S. D., Fabian, V. A., & Jones, T. M. (1996). Apolipoprotein-E genotyping in the diagnosis of Alzheimer's disease in an autopsy confirmed series. Lancet, 348, 483.
7. Kamboh, M. I, Sanghera, D. K., Ferrell, R. E., & DeKosky, S. T. (1995). APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nature and Genetics, 10, 486-488.
8. Khachaturian, Z. S. (1985). Diagnosis of Alzheimer's disease. Archives of Neurology, 42, 1097-1105.
9. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., et al. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
10. Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., et al. (1991). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): 2. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology, 41, 479-486.
11. Okuizumi, K., Onodera, O., Namba, Y., Ikeda, K., Yamamoto, T., et al. (1995). Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nature and Genetics, 11, 207-209.
12. Pericak-Vance, M. A., Conneally, P. M., Small, G. W., Saunders, A. M., Yamaoka, L., et al. (1995). The search for additional Alzheimer disease (AD) genes. In A. D. Roses, K. Weisgraber, & Y. Cristen (Eds.), Research and perspectives in Alzheimer's disease (pp. 180-186). Berlin: Springer-Verlag.
13. Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., et al. (1995). Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. New England Journal of Medicine, 333, 1242-1247.
14. Pritchard, M. L., Saunders, A. M., Gaskell, P. C., Small, G. W., Conneally, P. M., et al. (1996). No association between very low density lipoprotein receptor (VLDL-r) and Alzheimer disease in American Caucasians. Neuroscience Letters, 209, 105-108.
15. Roses, A. D. (1994). Apolipoprotein E affects the rate of Alzheimer disease expression: Beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. Journal of Neuropathology and Experimental Neurology, 53, 429-437.
16. Roses, A. D. (1996a). Apolipoprotein E alleles as risk factors in Alzheimer disease. Annual Reviews in Medicine, 47, 387-400.
17. Roses, A. D. (1996b). Apolipoprotein E and Alzheimer's disease. In R. N. Rosenberg, S. B. Prusiner, S. DiMauro, & R. L. Barchi (Eds.), The molecular and genetic basis of neurological disease (2nd ed.), Stoneham, MA: Butterworth-Heinemann.
18. Roses, A. D. (1996c). Apolipoprotein E genotype: Utility in clinical practice in Alzheimer's disease. Journal of the American Gerontological Society, 44, 1-3.
19. Roses, A. D. (1996d). A new paradigm for clinical dementia evaluations: Alzheimer disease and apolipoprotein E genotypes. In S. G. Post & P. J. Whitehouse (Eds.), Ethics, genetics and Alzheimer disease (Chap. 4). Baltimore: Johns Hopkins University Press.
20. Saunders, A. M., Hulette, C., Welsh, K. A., Schmechel, D. E., Crain, B., et al. (1996). Specificity, sensitivity and predictive value of apolipoprotein E genotyping in a consecutive autopsy series of sporadic Alzheimer disease. Lancet, 348, 90-93.
21. Saunders, A. M., Strittmatter, W. J., Schmechel, D., St George-Hyslop, P. H., Pericak-Vance, M. A., et al. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology, 43, 1467-1472.
22. Scott, W. K., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1996). Presenilin-1 polymorphism and Alzheimer's disease. Lancet, 347, 1560.
23. Slooter, A. J., Breteler, M. M. B., Ott, A., Van Broeckhoven, C., & van Duijn, C. M. (1996). APOE genotyping in differential diagnosis of Alzheimer's disease. Lancet, 348, 334.
24. Smith, A. D., Jobst, K. A., Johnston, C., Joachim, C., & Nagy, Z. (1996). Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease. Lancet, 348, 483-484.
25. Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak, V. M., Enghild, J., et al. (1993). Apolipoprotein E: Highavidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Science USA, 90, 1977-1981.
26. van Duijn, C. M., de Knijff, P., Wehnert, A., De Voecht, J., Bronzova, J. B., et al. (1995). The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Annals of Neurology, 37, 605-610.
27. Welsh-Bohmer, K. A., Gearing, M., Saunders, A. M., Roses, A. D., & Mirra, S. (in press). Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer's disease (CERAD). Annals of Neurology.
28. Wragg, M., Hutton, M., Talbot, C., Busfield, P., Han, S. W., et al. (1996). Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Lancet, 347, 509-512.